Atara Biotherapeutics (ATRA) Prepaid Assets (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Prepaid Assets came in at $3.8 million in Q1 2026, down 11.74% YoY from $4.3 million in Q1 2025, and up 53.94% on a QoQ basis from $2.5 million in Q4 2025.
Atara Biotherapeutics (ATRA) Prepaid Assets (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Prepaid Assets data on file, last reported at $3.8 million in Q1 2026.
- Quarterly Prepaid Assets fell 11.74% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (down 11.74% YoY) and the FY2025 annual result came in at $2.5 million, down 75.51% from the prior year.
- Prepaid Assets improved to $3.8 million in Q1 2026, from $2.5 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $16.0 million in Q3 2022 to a low of $2.4 million in Q2 2025.
- A 5-year average of $8.2 million and a median of $9.2 million in 2024 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2024 — Prepaid Assets soared 63.57% — and 2025, when it sank 75.51%.
- Tracing ATRA's Prepaid Assets over 5 years: stood at $10.3 million in 2022, then slumped by 40.01% to $6.2 million in 2023, then surged by 63.57% to $10.1 million in 2024, then slumped by 75.51% to $2.5 million in 2025, then soared by 53.94% to $3.8 million in 2026.
- The last three Prepaid Assets figures came in at $3.8 million (Q1 2026), $2.5 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Atara Biotherapeutics | 141.08 Mn | 124.53 Mn | 439,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.34 Mn |
| Mar 31, 2026 | 3.81 Mn |
| Dec 31, 2025 | 2.48 Mn |
| Sep 30, 2025 | 2.81 Mn |
| Jun 30, 2025 | 2.45 Mn |
| Mar 31, 2025 | 4.32 Mn |
| Dec 31, 2024 | 10.12 Mn |
| Sep 30, 2024 | 9.21 Mn |
| Jun 30, 2024 | 5.80 Mn |
| Mar 31, 2024 | 8.13 Mn |
| Dec 31, 2023 | 6.18 Mn |
| Sep 30, 2023 | 9.39 Mn |
| Jun 30, 2023 | 10.16 Mn |
| Mar 31, 2023 | 12.89 Mn |
| Dec 31, 2022 | 10.31 Mn |
| Sep 30, 2022 | 16.05 Mn |
| Jun 30, 2022 | 13.69 Mn |
| Mar 31, 2022 | 11.57 Mn |
| Dec 31, 2021 | 12.37 Mn |
| Sep 30, 2021 | 12.06 Mn |